Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | RRM1 | P23921 | 2/20 | 0.39 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690278 | 0.86 | LMNA (0.39) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL12565316 | 0.79 | LMNA (0.42) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL91638 | 0.79 | LMNA (0.42) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL31104487 | 0.79 | LMNA (0.68) | LMNAMAPTKDM4E | |
| SCHEMBL20480683 | 0.77 | MAPT (0.61) | LMNAMAPTKDM4E | |
| SCHEMBL19682927 | 0.76 | MAPT (0.39) | LMNAMAPTKDM4E | |
| SCHEMBL19682938 | 0.76 | CHRM2 (0.40) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL14706668 | 0.76 | LMNA (0.49) | LMNAMAPTCHRM2CHRM1RRM1 | |
| SCHEMBL25319448 | 0.74 | HTR2A (0.34) | — | |
| SCHEMBL25165937 | 0.72 | MAOB (0.40) | LMNAMAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| US-12344588-B2 | Sulfonamide compounds and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-07-01 | — | — | US | disclosed |
| CN-111386260-B | Sulfonamide compounds and uses thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-3466934-B1 | SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-11634395-B2 | Sulfonamide compound or salt thereof | Taiho Pharmaceutial Co., Ltd. (JP) | 2023-04-25 | — | — | US | disclosed |
| CN-109563057-B | Sulfonamide compound or salt thereof | 大鹏药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200361883-A1 | Sulfonamide Compounds and Use Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-19 | — | — | US | disclosed |
| EP-3717462-A1 | SULFONAMIDE COMPOUNDS AND USE THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| CN-111386260-A | Sulfonamide compound and use thereof | 大鹏药品工业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | LMNA 3354/4885MAPT 4312/4885CHRM2 4302/4885 |
| US-20200361883-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | LMNA 2463/4885MAPT 1137/4885CHRM2 3967/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | LMNA 3354/4885MAPT 4312/4885CHRM2 4302/4885 |
| US-20250223270-A1 | Sulfonamide Compounds and Use Thereof | STS, SULT2A1, TPST2 | LMNA 2463/4885MAPT 1137/4885CHRM2 3967/4885 |
| US-12344588-B2 | Sulfonamide compounds and use thereof | STS, SULT2A1, TPST2 | LMNA 2463/4885MAPT 1137/4885CHRM2 3967/4885 |
| US-11634395-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | LMNA 3354/4885MAPT 4312/4885CHRM2 4302/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | LMNA 3925/4885MAPT 4815/4885CHRM2 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.